While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Biohaven wielded meals at high-end restaurants and paid speaking opportunities to induce healthcare providers to prescribe ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, including Zepbound®BOSTON and SAN DIEGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- ...

These four top dividend stocks offer dependable passive income streams and solid total return, and they are too cheap to ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

The DOJ announces Pfizer agreed to pay nearly $60 million to resolve false claims allegations. The SEC creates a task force ...

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the years. While not all dividend stocks are the same, finding great companies ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

Pfizer’s subsidiary Biohaven has agreed to a settlement nearing $60 million to resolve allegations of false claims related to ...

Pfizer (PFE) colorectal cancer therapy Braftovi as part of a drug combo indicates a favorable objective response rate in a ...